OctoPlus extends development agreement with ESBATech

Published: 24-Feb-2011
Research & Development Pharmaceutical

For controlled release product for ophthalmic indications


OctoPlus has entered into an agreement with ESBATech, a Biomedical Research Unit of Alcon, based in Zurich, Switzerland, for the development of a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.

The agreement includes process development, scale-up and manufacturing for pre-clinical studies.

Financial details were not disclosed, but the Dutch firm said it would make a material contribution to its annual revenues in 2011.

This drug delivery technology evaluation project started in 2009. OctoPlus evaluated the feasibility of a controlled release formulation that combines an ESBATech proprietary eye care ingredient with the OctoPlus drug delivery technology PolyActive.

Jan Egberts, chief executive of OctoPlus, said: ‘I am delighted to see the success of our technology further validated in a product from such a prestigious company as ESBATech. We look forward to bringing this product to the next phase for ESBATech.

‘In addition to Locteron, this programme is now next in line in the commercialisation of the PolyActive controlled release technology.’

  • Companies:
  • OctoPlus
  • ESBATech
  • Alcon Group
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Future drug success is all in the delivery

Read more
Today, the mode of delivery can play a huge part in drug choice and success, thus new delivery technologies are proving to be a lucrative draw for drug formulators in all therapy categories. Susan Birks reports on market progress and predicted growth in the various categories

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  3. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Future drug success is all in the delivery

Today, the mode of delivery can play a huge part in drug choice and success, thus new delivery technologies are proving to be a lucrative draw for drug formulators in all therapy categories. Susan Birks reports on market progress and predicted growth in the various categories
Drug Delivery

Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m

Aims to build a research base in Leiden, The Netherlands
Manufacturing

OctoPlus signs agreement with pharma company to develop controlled release formulation

Of a therapeutic compound for local delivery into joints
Manufacturing

Octoplus extends drug delivery contract with Top-5 pharma company

Will combine product candidate with Octoplus PolyActive drug delivery technology
Finance

Novartis profit and sales up in Q2

Strong contribution from the Alcon eye care division
Finance

Novartis starts construction of US$500m plant in St Petersburg

Will produce new pharmaceuticals and generics for the Russian market
Drug Delivery

OctoPlus signs controlled release technology deal with US firm

Will use PolyActive technology to develop compound
Subscribe now